ArticleJournal of applied genetics2025
Association of polymorphisms of antioxidants (GSTM1/T1) and inflammation-related genes (CXCL8, IL-33, and IL-6) with chronic obstructive pulmonary disease (COPD).
Article in Journal of applied genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality globally. COPD, within its context of disease etiology, is characterized by chronic inflammation of the lungs. It is distinguished by the aberrant production of oxidants, inflammatory cytokines, dysregulated immune cell activity, and remodeling of the airways. In this study, we analyzed the polymorphic association of antioxidants (GSTM1/T1) and inflammation-related genes (CXCL8, IL-33, and IL-6) with COPD. A case-control study was conducted with 227 subjects (116 healthy controls and 111 COPD cases). GSTM1/T1 genes were amplified by multiplex PCR' and inflammatory genes (CXCL8, IL-33, and IL-6) were genotyped using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. GSTM1/T1 gene deletion rates in the COPD group were significantly higher than those in the control group (GSTM1: OR = 11.85, CI = 4.033-34.79, P < 0.0001; GSTT1: OR = 2.303, CI = 1.206-4.399, P = 0.0113). In addition, our research revealed a significant association between the combined GSTM1/T1 null genotype and increased susceptibility to COPD (OR = 18.66, CI = 2.345-148.5, P = 0.0003). A significantly increased frequency of the "CC" genotype of the CXCL8 (rs2227532) gene variant (OR = 7.50, CI = 2.429-23.16, P < 0.0001) was observed in COPD patients compared to the control group. However, there was no significant association of the IL-33 (rs7044343) polymorphism between healthy controls and COPD patients. The IL-6 (rs2069860) gene variant was found to be monomorphic. As a result of the investigation, it was concluded that individuals with the null genotype of GSTM1/T1 combined and the presence of the CXCL8 (rs2227532) gene variant have a higher likelihood of developing COPD.
Indexed as
Identifiers
41193663What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.